Fox Business - The Power to Prosper
Search Site

Wednesday, April 7, 2010 as of 11:14 AM ET

Vertex Pharmaceuticals

Vertex Pharmaceuticals

Vertex Pharmaceuticals is an American biotechnology company based in Cambridge, Massachusetts.

Read More at Wikipedia ›

Related Topics

  1. Pharmaceuticals
  2. Watson Pharmaceuticals
  3. Merck
  4. Gilead Sciences
  5. Amylin Pharmaceuticals
  6. Regeneron Pharmaceuticals
Get updates on Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, Medivation Among Stocks Hitting 52-Week Highs Monday

These stocks struck one-year highs:The share price of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) climbed today, reaching and then surpassing its previous 52-week high of $64.

50. In spite of its performance and peak price of $65.37, the stock was trading on below-average volume. Shares are trading at a volume of 4.1 million at a price bump of 4.7%. The stock is trading 52% above its 50-day moving average and 40.3% above its 200-day moving average.The share price of Medivation (NASDAQ:MDVN) increased today, reaching and then surpassing its previous 52-week high of $84.42. The stock was trading on above-average volume. Shares have gained 3.4% on volume of 717,933 shares. The stock has risen $17.89 (26.3%) over the last three months from a price of $67.96 on February 15, 2012. The stock is trading 11.9% above its 50-day moving average and 31.2% above its 200-day moving average.While trading on below-average volume, US Airways Group (NYSE:LCC) improved today, reaching and then surpas...

Read More ›

  1. Abbott Drugs Suppress Hepatitis C Virus In 2 Mid-Stage Studies

    Experimental drugs from Abbott Laboratories (ABT) suppressed the hepatitis C virus in most patients in two small, mid-stage studies.The results unveiled Wednesday co...

  2. Achillion, Vertex Rally On Gilead's Woes

    Shares of Achillion Pharmaceuticals rallied 23% to $10.77 on Friday after Gilead Sciences ' released disappointing study results for its drug candidate GS-7977, a tr...

  3. Patients On Gilead's Hepatitis C Drug Relapse In Trial

    Gilead Sciences Inc. (GILD) said a majority of hepatitis C patients in one arm of a clinical trial had a relapse in their disease after being treated with an experim...

  4. Merck Swings To 4Q Profit; Sales Up 4%

    Merck & Co. (MRK) swung to a fourth-quarter profit from a year-earlier loss that was weighed down by an asset writedown for a drug-research setback, while sales inch...

  5. Vertex Jumps 9% On FDA Approval

    Shares of Vertex Pharmaceuticals jumped 9% to $37.80 on Tuesday on news that the U.S. Food and Drug Administration has approved its drug Kalydeco, also known as ivac...

  6. Vertex Jumps On CEO Update

    Shares of Vertex Pharmaceuticals jumped 8% on Friday in the wake of news that Jeffrey Leiden will succeed Matthew Emmens as chief executive officer on Feb. 1, 2012. ...

  7. Bristol, J&J Join Forces on Hepatitis Treatment

    Bristol-Myers Squibb Co and Johnson & Johnson plan to jointly develop experimental treatments for hepatitis C in a market worth billions of dollars.The drugs being d...

  8. Vertex Slides 8% On Competitive Concerns

    Shares of Vertex Pharmaceuticals slid sharply for the second day on Tuesday on concerns that its new hepatitis C drug Incivek could soon be facing stiff competition....

  9. Inhibitex Rallies As Vertex Slides

    BOSTON -- Shares of Inhibitex Inc. shot up 14% to $9.70, after soaring over 100% on Friday, in the wake of positive clinical data for its hepatitis C drug candidate ...

  10. Inhibitex Rallies As Vertex Slides

    Shares of Inhibitex Inc. shot up 14% to $9.70, after soaring over 100% on Friday, in the wake of positive clinical data for its hepatitis C drug candidate INX-189. I...

  11. Vertex Hepatitis-C Drug Approved in Canada

    Vertex Pharmaceuticals ’ (NASDAQ:VRTX) treatment for chronic hepatitis C was approved by Health Canada after it showed higher rates of viral cure compared to its riv...

  12. FDA Sees Safety Issue With Merck Hepatitis Drug

    A proposed Merck & Co medicine eliminated the liver-destroying hepatitis C virus although anemia and other safety concerns remained for the potential blockbuster dru...

  1. Vertex Climbs On Analyst Upgrade

    Vertex Pharmaceuticals shares rose 5% to $2.90 on Monday after analysts at J.P. Morgan upped their rating of the stock to overweight from neutral, and price target t...

  2. Health Care Sector Wrap

    During trading today, the Health Care sector (XLV) showed little change while the S&P 500 fell 0.4%.Although down today, the ETF, as a as a proxy for sector performa...

  3. Vertex Pharmaceuticals Incorporated, Linkedin Corporation Among Stocks Up on High Volume Tuesday

    These stocks are up on above-average volume today:Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was up on high volume today, trading with volume of 16 million, o...

  4. Vertex Pharmaceuticals Incorporated, Vitamin Shoppe, Other Stocks Hit 52-Week Highs Tuesday

    These are the nine most popular stocks that rose to 52-week highs:The share price of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) improved today, reaching and t...

  5. Health Care Sector Wrap

    The Health Care sector (XLV) held steady during a trading day that saw the S&P 500 grow 0.1%.Despite being down today, the ETF, as a as a proxy for sector performanc...

  6. Vertex Shares Soar On Cystic Fibrosis Study

    Shares of Vertex Pharmaceuticals soared 44% to $54.00 on Monday after it reported positive early data from an on-going Phase II clinical trial testing its new drug K...

  7. Abbott Drugs Suppress Hepatitis C Virus In 2 Studies

    Experimental drugs from Abbott Laboratories (ABT) suppressed the hepatitis C virus in most patients in two small, mid-stage studies.The results unveiled Wednesday co...

‹ Prev12Next ›
Freebase CC-BY
Source: Vertex Pharmaceuticals on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL